| Bioactivity | AILNYVANK-(Lys-13C6,15N2) is 13C and 15N labeled AILNYVANK-(Lys)[1]. |
| Invitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> AILNYVANK-(Lys-13C6,15N2) 相关抗体: |
| Sequence | Ala-Ile-Leu-Asn-Tyr-Val-Ala-Asn-{Lys(13C6,15N2)} |
| Shortening | AILNYVAN-{Lys(13C6,15N2)} |
| Formula | C4013C6H76N1015N2O13 |
| Molar Mass | 1013.11 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |